IPM Take
This is personalised medicine’s least glamorous failure, and one of its most serious. A system cannot claim to deliver precision oncology while it cannot guarantee the backbone medicines that make routine cancer care possible. The problem is not scientific complexity. It is political neglect of generic-drug manufacturing, procurement and supply resilience.
Executive Summary
Axios reported that U.S. cancer centres are monitoring renewed shortages of carboplatin, cisplatin and ifosfamide, raising concerns that treatment may need to be delayed, changed or rationed. Hospital fill rates for cisplatin reportedly fell to 66% in June. The American Society of Health-System Pharmacists lists ongoing shortages for carboplatin, cisplatin and ifosfamide, with some manufacturers reporting back orders, allocations, limited stock or no firm resupply date.
Why it matters
- Patients / advocates: A shortage can mean a treatment change at the worst possible moment, even when the intended regimen is established and clinically appropriate.
- Clinicians: There is no universal substitute for platinum chemotherapy. Alternatives must be judged patient by patient, tumour by tumour.
- Hospitals / providers: Cancer centres are forced into contingency planning, inventory monitoring and difficult allocation decisions.
- Public authorities: Essential-medicines policy is still failing to protect drugs that are cheap, widely used and clinically indispensable.
The warning signs are familiar. So is the failure to act before they become a crisis.
U.S. cancer centres are again confronting shortages of old, generic chemotherapy medicines that remain central to modern oncology. Carboplatin, cisplatin and ifosfamide are not niche products. They sit inside treatment pathways for multiple cancers, including curative-intent regimens where delay or substitution is not a minor administrative inconvenience.
Axios reported that hospital fill rates for cisplatin fell to 66% in June. The American Society of Health-System Pharmacists now lists active shortages across carboplatin, cisplatin and ifosfamide. For carboplatin, ASHP states that supply is insufficient for usual ordering. Several products are on back order, some are available only in limited supply, and others are being allocated. The guidance is blunt: assess available stock before starting treatment, consider an alternative regimen where necessary, and make the decision with oncology expertise.
That is not business as usual. It is rationing architecture.
The language matters. No one should casually claim that every cancer centre in the United States is already withholding care. But hospitals are being pushed into exactly the kind of planning that makes patients fear it: deciding which stock can be protected, which regimens can be adjusted, and which patients can wait least safely.
The market logic behind this is as old as the drugs themselves. Generic injectable medicines are often made on thin margins. Raw-material costs move. Manufacturing capacity is concentrated. Pricing rules can be rigid. A company exits, a shipment slips, demand rises, and an entire treatment pathway becomes vulnerable.
The policy response cannot be another emergency call once shelves are already thinning. Cancer care needs supply-chain intelligence before shortage alerts, coordinated procurement, meaningful incentives for reliable manufacturing, and public accountability when essential medicines become unavailable.
Innovation is not only a new molecule. Sometimes it is making sure the old one is there.
